Noden Pharma patents expiration
1. Goprelto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10894012 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10857095 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10231961 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10413505 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US9867815 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US11040032 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10016407 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10149843 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10420760 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10933060 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10973811 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10987347 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes; Method of administering a local anesthetic to the mucous membr...
Dosage: SOLUTION;NASAL
GOPRELTO family patents
2. Tekturna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5559111 | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
|
US5559111 (Pediatric) | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan, 2019
(5 years ago) | |
| US8617595 | NODEN PHARMA | Galenic formulations of organic compounds |
Feb, 2026
(1 year, 9 months from now) | |
|
US8617595 (Pediatric) | NODEN PHARMA | Galenic formulations of organic compounds |
Aug, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 05 March, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TEKTURNA family patents
3. Tekturna Hct patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5559111 | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
|
US5559111 (Pediatric) | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan, 2019
(5 years ago) | |
| US9023893 | NODEN PHARMA | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Mar, 2022
(2 years ago) | |
| US8618172 | NODEN PHARMA | Galenical formulations of organic compounds |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Indication(I-600) | Jul 16, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 18 January, 2008
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TEKTURNA HCT family patents